Clinical Trials Directory

Trials / Conditions / Systemic Mastocytosis

Systemic Mastocytosis

18 registered clinical trials studyying Systemic Mastocytosis — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingMastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis
NCT07142473
Fondazione IRCCS Policlinico San Matteo di Pavia—
CompletedFlotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NCT04681105
City of Hope Medical CenterPhase 1
WithdrawnFlotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
NCT03739606
City of Hope Medical CenterPhase 2
TerminatedGTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
NCT03214666
GT Biopharma, Inc.Phase 1 / Phase 2
CompletedInterest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
NCT03401060
Assistance Publique - Hôpitaux de ParisPhase 3
CompletedDiagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
NCT02441166
University Hospital, ToulouseN/A
CompletedTreatment of Indolent Systemic Mastocytosis With PA101
NCT02478957
Patara PharmaPhase 2
TerminatedIbrutinib in Treating Patients With Advanced Systemic Mastocytosis
NCT02415608
Jason Robert GotlibPhase 2
CompletedBrentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
NCT01807598
Jason Robert GotlibPhase 2
UnknownCladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
NCT01602939
Hospital Virgen de la SaludPhase 2 / Phase 3
CompletedImatinib in KIT-negative Systemic Mastocytosis
NCT01297777
Hospital Virgen de la SaludPhase 4
UnknownEvaluation of Response of Dasatinib to Treat Mastocytosis
NCT00979160
Federico II UniversityPhase 2
TerminatedObatoclax for Systemic Mastocytosis
NCT00918931
M.D. Anderson Cancer CenterPhase 2
CompletedEverolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
NCT00449748
M.D. Anderson Cancer CenterPhase 2
CompletedA Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
NCT00109707
Novartis PharmaceuticalsPhase 1 / Phase 2
CompletedUse of Tamoxifen in Systemic Mastocytosis
NCT01334996
Mayo Clinic—
CompletedImatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
NCT00171912
Novartis PharmaceuticalsPhase 2
CompletedOntak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
NCT00493129
M.D. Anderson Cancer CenterPhase 2